Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 53Lymphoma, Mantle-Cell 34Lymphoma, Large B-Cell, Diffuse 18Lymphoma, Follicular 18Lymphoma 15Lymphoma, Non-Hodgkin 13Waldenstrom Macroglobulinemia 12Lymphoma, B-Cell 12Recurrence 9Lymphoma, B-Cell, Marginal Zone 9Leukemia 6Bronchiolitis Obliterans Syndrome 6Multiple Myeloma 5Leukemia, Lymphoid 5Leukemia, B-Cell 5Hodgkin Disease 5Hematologic Neoplasms 4Burkitt Lymphoma 4Neoplasms 3Graft vs Host Disease 3Lung Neoplasms 2Leukemia, Myeloid, Acute 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Chromosome 17 deletion 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1

Interventions

fludarabine phosphate 2Whole-Body Irradiation 2Mycophenolic Acid 2obinutuzumab 1nelarabine 1letermovir 1ibrutinib 1carmustine, poliferprosan 20 drug combination 1Tacrolimus 1Stem Cell Transplantation 1Peripheral Blood Stem Cell Transplantation 1Melphalan 1Lenalidomide 1Hematopoietic Stem Cell Transplantation 1Etoposide 1Cytarabine 1Cyclosporins 1Cyclosporine 1Cyclophosphamide 1Carmustine 16-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leukemia, Prolymphocytic, B-Cell × ibrutinib × Clear all
NCT01886859 2022-09-26

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
27 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡